ClinicalTrials.gov record
Completed Phase 1 Interventional

INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease

ClinicalTrials.gov ID: NCT01164163

Public ClinicalTrials.gov record NCT01164163. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 8:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I Study of JAK Inhibition (INCB018424) in Children With Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms

Study identification

NCT ID
NCT01164163
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Children's Oncology Group
Network
Enrollment
49 participants

Conditions and interventions

Interventions

  • laboratory biomarker analysis Other
  • pharmacological study Other
  • ruxolitinib phosphate Drug

Other · Drug

Eligibility (public fields only)

Age range
1 Year to 21 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2010
Primary completion
Sep 30, 2014
Completion
Not listed
Last update posted
Oct 22, 2014

Started 2010

United States locations

U.S. sites
24
U.S. states
20
U.S. cities
24
Facility City State ZIP Site status
UAB Comprehensive Cancer Center Birmingham Alabama 35294
Children's Hospital of Orange County Orange California 92868
UCSF Helen Diller Family Comprehensive Cancer Center San Francisco California 94115
Children's Hospital Colorado Center for Cancer and Blood Disorders Aurora Colorado 80045
Children's National Medical Center Washington D.C. District of Columbia 20010-2970
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus Atlanta Georgia 30322
Children's Memorial Hospital - Chicago Chicago Illinois 60611
Riley's Children Cancer Center at Riley Hospital for Children Indianapolis Indiana 46202
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore Maryland 21231-2410
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office Bethesda Maryland 20892-1182
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute Boston Massachusetts 02115
C.S. Mott Children's Hospital at University of Michigan Medical Center Ann Arbor Michigan 48109-0286
Masonic Cancer Center at University of Minnesota Minneapolis Minnesota 55455
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis St Louis Missouri 63110
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center New York New York 10032
Cincinnati Children's Hospital Medical Center Cincinnati Ohio 45229-3039
Knight Cancer Institute at Oregon Health and Science University Portland Oregon 97239-3098
Children's Hospital of Philadelphia Philadelphia Pennsylvania 19104
Children's Hospital of Pittsburgh of UPMC Pittsburgh Pennsylvania 15213
St. Jude Children's Research Hospital Memphis Tennessee 38105
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas Dallas Texas 75390
Baylor University Medical Center - Houston Houston Texas 77030-2399
Children's Hospital and Regional Medical Center - Seattle Seattle Washington 98105
Midwest Children's Cancer Center at Children's Hospital of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01164163, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 22, 2014 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01164163 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →